Compare FHN & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FHN | TGTX |
|---|---|---|
| Founded | 1864 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.0B | 5.5B |
| IPO Year | N/A | 1995 |
| Metric | FHN | TGTX |
|---|---|---|
| Price | $24.59 | $30.80 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 18 | 4 |
| Target Price | $24.61 | ★ $54.75 |
| AVG Volume (30 Days) | ★ 5.5M | 1.4M |
| Earning Date | 01-15-2026 | 11-03-2025 |
| Dividend Yield | ★ 2.45% | N/A |
| EPS Growth | ★ 20.88 | N/A |
| EPS | 1.65 | ★ 2.78 |
| Revenue | ★ $3,184,000,000.00 | $531,898,000.00 |
| Revenue This Year | $10.95 | $87.88 |
| Revenue Next Year | $2.82 | $48.75 |
| P/E Ratio | $14.81 | ★ $11.19 |
| Revenue Growth | 3.68 | ★ 100.88 |
| 52 Week Low | $15.19 | $25.28 |
| 52 Week High | $24.75 | $46.48 |
| Indicator | FHN | TGTX |
|---|---|---|
| Relative Strength Index (RSI) | 72.25 | 46.61 |
| Support Level | $23.54 | $29.79 |
| Resistance Level | $24.75 | $31.37 |
| Average True Range (ATR) | 0.43 | 1.03 |
| MACD | 0.09 | 0.03 |
| Stochastic Oscillator | 88.68 | 49.61 |
First Horizon Corp is the parent company of First Tennessee Bank, a prominent regional bank with about 200 branches around Tennessee. The company's reportable segments are: Commercial, Consumer & Wealth, Wholesale, and Corporate. The majority of its revenue is generated from Commercial, Consumer & Wealth. The Commercial, Consumer & Wealth segment offers financial products and services, including traditional lending and deposit taking, to commercial and consumer clients in the southern USA and other selected markets.
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.